Boston Scientific Cuts Medinol Ties With Express2 Stent Approval In U.S.
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will no longer depend on Israeli firm Medinol for its coronary stents in the U.S. after gaining FDA approval of its Express2 stent Sept. 12
You may also be interested in...
Express2 Revises Boston Scientific’s U.S. Stent Sales; Japan Nir Sales Sag
Rapid uptake of the Express2 stent confirms Boston Scientific's expectation that the internally developed platform will revitalize its languishing stent business as the company awaits the introduction of a drug-eluting counterpart
Express2 Revises Boston Scientific’s U.S. Stent Sales; Japan Nir Sales Sag
Rapid uptake of the Express2 stent confirms Boston Scientific's expectation that the internally developed platform will revitalize its languishing stent business as the company awaits the introduction of a drug-eluting counterpart
Gore Gains Coronary Stent Market Entry With Nirflex Under Medinol Pact
W.L. Gore & Associates will enter the U.S. coronary stent market upon FDA approval of Medinol's Nirflex stent under a Sept. 24 worldwide stent distribution and collaboration agreement